Suxiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suxiang Chen has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Rakesh Naduvile Veedu
Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University, Murdoch, WA 6150, Australia
24 shared publications - Bal Hari Poudel
Personalised Medicine Centre, Health Futures Institute, Murdoch University, Murdoch, WA 6150, Australia
5 shared publications - Bao Tri Le
Centre for Comparative Genomics
5 shared publications Kamal Rahimizadeh
Personalised Medicine Centre, Health Futures Institute, Murdoch University, Australia
4 shared publications- Madhuri Chakravarthy
Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia
4 shared publications Tao Wang
4 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 21, 724-737
Lipid metabolism dysregulation in Parkinson’s disease: A Mendelian randomization and transcriptomic analysis
- 26 August 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 21, 724-737
Open AccessLipid metabolism dysregulation in Parkinson’s disease: A Mendelian randomization and transcriptomic analysis
- Open Access
Survivin-Targeting Antisense Oligonucleotides in Cancer Therapy
Survivin (BIRC5) is a key inhibitor of apoptosis that is highly overexpressed in many cancers, where it promotes tumour cell survival, mitotic progression, and resistance to therapy. Because survivin is largely absent from normal adult tissues, it represents a selective and promising target for cancer treatment. Antisense oligonucleotides (ASOs) provide a precise approach to silence survivin by targeting its transcripts. Preclinical studies have shown that ASO-mediated reduction of survivin is associated with increased cancer cell death, inhibition of tumour growth, and enhanced sensitivity to other treatments. Early-phase clinical trials of survivin-targeting ASOs have shown evidence of target engagement but ultimately failed to demonstrate consistent clinical benefit and/or encountered dose-limiting toxicities, which hindered their further development. This review outlines survivin’s central role in cancer biology, the principles of ASO therapeutics (sequence design, mechanisms of action, chemical modifications, and delivery strategies), and the progress in preclinical and clinical development of survivin-targeting ASOs, while also discussing key challenges that may contribute to their clinical limitations, including inefficient delivery, off-target effects, and systemic toxicities. Collectively, the current status of survivin-targeting ASOs underscores the need for synergistic optimization of delivery platforms and molecular chemistry to improve efficacy and safety, thereby enabling their use in personalised and combination cancer treatment approaches.
Open AccessSurvivin-Targeting Antisense Oligonucleotides in Cancer Therapy
Survivin (BIRC5) is a key inhibitor of apoptosis that is highly overexpressed in many cancers, where it promotes tumour cell survival, mitotic progression, and resistance to therapy. Because survivin is largely absent from normal adult tissues, it represents a selective and promising target for cancer treatment. Antisense oligonucleotides (ASOs) provide a precise approach to silence survivin by targeting its transcripts. Preclinical studies have shown that ASO-mediated reduction of survivin is associated with increased cancer cell death, inhibition of tumour growth, and enhanced sensitivity to other treatments. Early-phase clinical trials of survivin-targeting ASOs have shown evidence of target engagement but ultimately failed to demonstrate consistent clinical benefit and/or encountered dose-limiting toxicities, which hindered their further development. This review outlines survivin’s central role in cancer biology, the principles of ASO therapeutics (sequence design, mechanisms of action, chemical modifications, and delivery strategies), and the progress in preclinical and clinical development of survivin-targeting ASOs, while also discussing key challenges that may contribute to their clinical limitations, including inefficient delivery, off-target effects, and systemic toxicities. Collectively, the current status of survivin-targeting ASOs underscores the need for synergistic optimization of delivery platforms and molecular chemistry to improve efficacy and safety, thereby enabling their use in personalised and combination cancer treatment approaches.
- Open Access
- 22 May 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (8) , 5328-5350
Targeting NAT10 with Remodelin reshapes the pro-fibrotic microenvironment in renal fibrogenesis via inhibiting exosome oversecretion from tubular cells
- 22 May 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (8) , 5328-5350
Open AccessTargeting NAT10 with Remodelin reshapes the pro-fibrotic microenvironment in renal fibrogenesis via inhibiting exosome oversecretion from tubular cells
- Open Access
- 4 April 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (2) , 102915
WDR91, an endosomal maturation protein, promotes antisense oligonucleotide activity
- 4 April 2026
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 37 (2) , 102915
Open AccessWDR91, an endosomal maturation protein, promotes antisense oligonucleotide activity
- Open Access
- 12 December 2025
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 250, 10784
Beginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications
Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn’t integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5′cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA’s molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.
- 12 December 2025
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 250, 10784
Open AccessBeginning of a new era of synthetic messenger RNA therapeutics: Comprehensive insights on mRNA drug design, development and applications
Messenger RNA (mRNA) therapeutics have significantly transformed contemporary medicine, particularly through their role as the active component in the SARS-CoV-2 vaccine. This remarkable achievement is the culmination of extensive research conducted over many years by scientists. The widespread administration of the COVID-19 vaccine has further accelerated research into the precise therapeutic potential of mRNA technologies. Since mRNA doesn’t integrate with the host genome, the safety and versatility of mRNA-based therapeutics make them an iconic candidate in targeted therapies. Due to a surge in innovation efforts, biomodification of the molecular signatures of mRNAs like the 5′cap, untranslated regions (UTRs), and the poly(A) tail are being developed to increase translation efficacy. Recent advancements in chemical modifications, codon optimization techniques, and targeted delivery methods have significantly enhanced the stability of synthetic mRNAs while concurrently reducing their immunogenicity. Various mRNA manufacturing and synthesizing methods are investigated in this review, focusing on their scalability and limitations. mRNA therapeutic strategies can be divided into protein replacement, immune modulation, and cellular modulation. This review explores mRNA’s molecular landscape and comprehensive utility, including applications in both clinical trials and commercial sectors.
- Open Access
- 16 November 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (4) , 102761
An LNA gapmer antisense oligonucleotide inhibitor of human NNMT
- 16 November 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (4) , 102761
Open AccessAn LNA gapmer antisense oligonucleotide inhibitor of human NNMT
- 6 October 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (87) , 17001-17004
Systematic evaluation of 2′- O -methyl RNA antisense oligonucleotides with limited phosphorothioate linkages for efficient splice switching
Herein, we report a systematic exploration of 2′-O-methyl (2′-OMe) antisense oligonucleotides (ASOs) with a stereo-random phosphodiester–phosphorothioate (PO–PS) backbone regarding their design, RNA binding affinity, nuclease resistance, and exon skipping efficacy. The results showed that ASOs having PO linkages arranged at the 3′-end exhibited higher exon skipping efficacy and slightly higher target binding affinity than their counterparts with PO linkages arranged at the 5′-end; and the residual length of ASOs can be still well protected from 3′-exonuclease after initial hydrolysis of as many as four successive PO linkages from the 3′-end. These findings provide insights and guidance for rational design of splice-switching ASOs with limited PS linkages.
- 6 October 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 61 (87) , 17001-17004
Systematic evaluation of 2′- O -methyl RNA antisense oligonucleotides with limited phosphorothioate linkages for efficient splice switching
Herein, we report a systematic exploration of 2′-O-methyl (2′-OMe) antisense oligonucleotides (ASOs) with a stereo-random phosphodiester–phosphorothioate (PO–PS) backbone regarding their design, RNA binding affinity, nuclease resistance, and exon skipping efficacy. The results showed that ASOs having PO linkages arranged at the 3′-end exhibited higher exon skipping efficacy and slightly higher target binding affinity than their counterparts with PO linkages arranged at the 5′-end; and the residual length of ASOs can be still well protected from 3′-exonuclease after initial hydrolysis of as many as four successive PO linkages from the 3′-end. These findings provide insights and guidance for rational design of splice-switching ASOs with limited PS linkages.
- Open Access
- 28 April 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (2)
A single stereogenic center matters: Development of stereodefined anti-tau PMO-gapmers
- 28 April 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (2)
Open AccessA single stereogenic center matters: Development of stereodefined anti-tau PMO-gapmers
- Open Access
- 22 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 883
Rational Design of Chimeric Antisense Oligonucleotides on a Mixed PO–PS Backbone for Splice-Switching Applications
Synthetic antisense oligonucleotides (ASOs) are emerging as an attractive platform to treat various diseases. By specifically binding to a target mRNA transcript through Watson–Crick base pairing, ASOs can alter gene expression in a desirable fashion to either rescue loss of function or downregulate pathogenic protein expression. To be clinically relevant, ASOs are generally synthesized using modified analogs to enhance resistance to enzymatic degradation and pharmacokinetic and dynamic properties. Phosphorothioate (PS) belongs to the first generation of modified analogs and has played a vital role in the majority of approved ASO drugs, mainly based on the RNase H mechanism. In contrast to RNase H-dependent ASOs that bind and cleave target mature mRNA, splice-switching oligonucleotides (SSOs) mainly bind and alter precursor mRNA splicing in the cell nucleus. To date, only one approved SSO (Nusinersen) possesses a PS backbone. Typically, the synthesis of PS oligonucleotides generates two types of stereoisomers that could potentially impact the ASO’s pharmaco-properties. This can be limited by introducing the naturally occurring phosphodiester (PO) linkage to the ASO sequence. In this study, towards fine-tuning the current strategy in designing SSOs, we reported the design, synthesis, and evaluation of several stereo-random SSOs on a mixed PO–PS backbone for their binding affinity, biological potency, and nuclease stability. Based on the results, we propose that a combination of PO and PS linkages could represent a promising approach toward limiting undesirable stereoisomers while not largely compromising the efficacy of SSOs.
- 22 July 2024
- Published by MDPI AG in Biomolecules
- Vol. 14 (7) , 883
Open AccessRational Design of Chimeric Antisense Oligonucleotides on a Mixed PO–PS Backbone for Splice-Switching Applications
Synthetic antisense oligonucleotides (ASOs) are emerging as an attractive platform to treat various diseases. By specifically binding to a target mRNA transcript through Watson–Crick base pairing, ASOs can alter gene expression in a desirable fashion to either rescue loss of function or downregulate pathogenic protein expression. To be clinically relevant, ASOs are generally synthesized using modified analogs to enhance resistance to enzymatic degradation and pharmacokinetic and dynamic properties. Phosphorothioate (PS) belongs to the first generation of modified analogs and has played a vital role in the majority of approved ASO drugs, mainly based on the RNase H mechanism. In contrast to RNase H-dependent ASOs that bind and cleave target mature mRNA, splice-switching oligonucleotides (SSOs) mainly bind and alter precursor mRNA splicing in the cell nucleus. To date, only one approved SSO (Nusinersen) possesses a PS backbone. Typically, the synthesis of PS oligonucleotides generates two types of stereoisomers that could potentially impact the ASO’s pharmaco-properties. This can be limited by introducing the naturally occurring phosphodiester (PO) linkage to the ASO sequence. In this study, towards fine-tuning the current strategy in designing SSOs, we reported the design, synthesis, and evaluation of several stereo-random SSOs on a mixed PO–PS backbone for their binding affinity, biological potency, and nuclease stability. Based on the results, we propose that a combination of PO and PS linkages could represent a promising approach toward limiting undesirable stereoisomers while not largely compromising the efficacy of SSOs.
- Open Access
- 22 April 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (19) , 13336-13341
Inhibition of survivin by 2′- O -methyl phosphorothioate-modified steric-blocking antisense oligonucleotides
We have designed and screened seven fully 2′- O -methyl phosphorothioate-modified steric-blocking ASOs for specific inhibition of BIRC5 expression. As a result, ASO-7 was identified as the lead sequence.
- 22 April 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (19) , 13336-13341
Open AccessInhibition of survivin by 2′- O -methyl phosphorothioate-modified steric-blocking antisense oligonucleotides
We have designed and screened seven fully 2′- O -methyl phosphorothioate-modified steric-blocking ASOs for specific inhibition of BIRC5 expression. As a result, ASO-7 was identified as the lead sequence.